Form 4: Paolo Pucci, Replimune Group Director, Reports Stock Option Grant

Director Paolo Pucci reports acquisition of stock options in Replimune Group, Inc.

Summary

• Paolo Pucci, a director of Replimune Group, Inc., filed a Form 4 on April 3, 2025.
• The report details a transaction on April 1, 2025, where Pucci acquired 32,000 stock options.
• These options have an exercise price of $8.40 and expire on April 1, 2035.
• The options vest entirely on April 1, 2026.
• Following the transaction, Pucci directly owns 32,000 derivative securities.

Sentiment

Score: 6

Explanation: Neutral sentiment as it's a standard regulatory filing detailing stock option grants. It doesn't inherently indicate positive or negative performance, but rather a routine transaction.

Positives

• The acquisition of stock options by a director can be seen as a positive sign, indicating confidence in the company's future performance.

Industry Context

This filing is a routine disclosure related to insider transactions, common in the biopharmaceutical industry where stock options are frequently used as part of executive compensation packages.

Stakeholder Impact

• The granting of stock options to a director could potentially align the director's interests with those of the shareholders.

Key Dates

Keywords

Form 4, stock options, Replimune Group, director, Pucci, beneficial ownership, securities